



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/614,363	07/07/2003	Horst Dollinger	01/1359	7879
28501	7590	08/28/2007	EXAMINER	
MICHAEL P. MORRIS			WANG, SHENGJUN	
BOEHRINGER INGELHEIM CORPORATION			ART UNIT	PAPER NUMBER
900 RIDGEURY ROAD			1617	
P. O. BOX 368				
RIDGEFIELD, CT 06877-0368			MAIL DATE	DELIVERY MODE
			08/28/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)
	10/614,363	DOLLINGER ET AL.
	Examiner	Art Unit
	Shengjun Wang	1617

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 31 May 2007.
- 2a) This action is **FINAL**. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-2, 4-14 is/are pending in the application.
- 4a) Of the above claim(s) 1,2,7-11,13 and 14 is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 4-6 and 12 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All b) Some * c) None of:
1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____. | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| | 6) <input type="checkbox"/> Other: _____. |

DETAILED ACTION

Receipt of applicants' amendments and remarks submitted May 31, 2007 is acknowledged.

Claim Rejections 35 U.S.C. 102

1. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

2. Claims 4 and 12 are rejected under 35 U.S.C. 102(b) as being clearly anticipated by Dollinger et al. (US 6,235,732, IDS).

3. Dollinger et al. teaches compounds of general formula (I) useful a therapeutical agents in pharmaceutical composition, wherein B may be CH₂CH₂, R₁ and R₂ may be hydrogen, alkyl, R₃ denotes hydrogen, C₁-6 alkyl, C₁-6 alkyl substituted by 1-3 fluorine, halogen, alkoxy, m is 1,2 or 3; and Z may be nitrogen containing ring, and A may be phenyl substituted by 1, 2, or 3 R₄, which is C₁-6 alkyl, C₁-6 alkyl substituted by 1-3 fluorine, halogen, etc. See, particularly, columns 1-2, and the claims. Compound 2-(3,5-Bistrifluoromethylphenyl)-2'-(2-methoxyphenyl)-2'-(4-cyclohexylpiperazine-1-yl)-diethylamine is particularly disclosed which meet all the limitation recited in claim 4. See, See, example 66, column 20, lines 1-28.

Claim Rejections 35 U.S.C. 103

1. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

Art Unit: 1617

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

4. Claims 5, 6 are rejected under 35 U.S.C. 103(a) as being unpatentable over Dollinger et al. (US 6,235,732, IDS).

5. Dollinger et al. teaches compounds of general formula (I) useful a therapeutical agents in pharmaceutical composition, wherein B may be CH₂CH₂, R1 and R2 may be hydrogen, alkyl, R3 denotes hydrogen, C₁₋₆ alkyl, C₁₋₆ alkyl substituted by 1-3 fluorine, halogen, alkoxy, m is 1,2 or 3; and Z may be nitrogen containing ring, and A may be phenyl substituted by 1, 2, or 3 R4, which is C₁₋₆ alkyl, C₁₋₆ alkyl substituted by 1-3 fluorine, halogen, etc. See, particularly, columns 1-2, and the claims. Compound 2-(3,5-Bistrifluoromethylphenyl)-2'-(2-methoxyphenyl)-2'-(4-cyclohexylpiperazine-1-yl)-diethylamine is particularly disclosed which meet all the limitation recited in claim 4. See, example 66, column 20, lines 1-28.

2. Dollinger et al. do not teach expressly a compound with the particular substituted phenyl, or unsubstituted phenyl, i.e., Ra, Rb, Rd and Re be hydrogen, and Rc be either a hydrogen or a substituent and a composition comprising the same.

However, it would have been *prima facie* obvious to a person of ordinary skill in the art, at the time the claimed the invention was made, to make a diethylamine similar to example 66, but with a unsubstituted or 4-substituted phenyl because Dollinger et al. teaches that all these compounds are similarly useful. Particularly, Dollinger et al. teaches that R3 denotes hydrogen, C₁₋₆ alkyl, C₁₋₆ alkyl substituted by 1-3 fluorine, halogen, alkoxy, m is 1,2 or 3. Therefore, by following the instruction of Dollingers et al, one of ordinary skill in the art would make the compounds herein with predictable properties.

Art Unit: 1617

3. Applicant's submission of an information disclosure statement under 37 CFR 1.97(c) with the fee set forth in 37 CFR 1.17(p) on May 31, 2007 prompted the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 609.04(b). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shengjun Wang whose telephone number is (571) 272-0632. The examiner can normally be reached on Monday to Friday from 7:00 am to 3:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan, can be reached on (571) 272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

Art Unit: 1617

applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).


SHENGJUN WANG
Shengjun Wang, EXAMINER
Primary Examiner
Art Unit 1617